Navigation Links
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Date:11/1/2008

rial with the general applicability of a 'real-world' study, since it included all patients at our clinic who initiated hepatitis C treatment and met basic eligibility criteria," said Professor Colombo. "The results from this study prove that treatment success rates in the real world can be comparable to those achieved in clinical trials. The study also demonstrates that PEGASYS regimens enable significantly more patients to achieve a SVR."

PEGASYS has demonstrated efficacy in a broad range of patient types, even those with poor prognostic factors.(2)(3)(4)(5)(6)

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS (ribavirin), is indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA-approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chroni
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
2. Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
3. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
4. Grapes May Aid a Bunch of Heart Risk Factors, U-M Animal Study Finds
5. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
6. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
7. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
10. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
11. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... LAWRENCE, Mass. , Dec. 22, 2014 /PRNewswire/ ... a leading manufacturer of innovative dialysis products, announced ... (FDA) has cleared its System One™ to perform ... sleeping, known as home nocturnal hemodialysis. NxStage,s® System ... cleared by the FDA for this indication. ...
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals ... 2a study of lonafarnib in patients with chronic ... conducted at the National Institutes of Health (NIH) ... .  The double-blinded, randomized, placebo-controlled, dose ascending study ... daily and 200 mg twice daily for 28 ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... , a leading provider of therapeutic drug monitoring and ... today the appointment of David Cohen to Chief Operating ... responsible for new business analysis and development to expand ... Millennium,s legislative initiatives and community outreach programs. ...
... Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast:What: ... presented at ESCWhen: , Wednesday, September 1, 2010 at 4:00 ... Live on the Internet.  Simply log onto our Web site listed ... a replay of the webcast will be available for a limited ...
Cached Medicine Technology:Millennium Laboratories Announces New Chief Operating Officer David Cohen 2
(Date:12/24/2014)... As 2014 draws to a close, ... investing time and money into a new or tankless ... specializes in tankless and eco-friendly products or service. Greenstar ... heater in 2015 to research “green” and environmentally friendly ... Home Services specializes in eco-friendly and environmentally conscious ...
(Date:12/24/2014)... York (PRWEB) December 24, 2014 In ... the United States rode bicycles, hand cycles and recumbent ... D.C. in the inaugural CanAm Veterans’ Challenge . ... non-profit World T.E.A.M. Sports about this inspiring ride, is ... more than 50 full color photographs taken during the ...
(Date:12/24/2014)... 23, 2014 (HealthDay News) -- Each year, more than ... the United States occur because of extreme heat conditions, ... study finds that heat stroke is the leading cause ... as kidney failure and urinary tract infections, also put ... soar. The new data should help health care ...
(Date:12/24/2014)... -- Though most patients with obsessive-compulsive disorder (OCD) can ... percent to 20 percent have a form of the ... However, patients with this so-called "refractory OCD" do ... brain surgery that disables certain brain networks believed to ... patients most likely to benefit from the surgery, known ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Tri-City Medical Center in Oceanside, Calif. The top ... B. E. Smith has recently placed more than 900 ... is a community owned, 397-bed, Gold Seal-approved, full-service acute-care ...
Breaking Medicine News(10 mins):Health News:Greenstar Home Services Offers Tankless Water Heater Advice to Local Homeowners 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 3Health News:Heat Stroke, Kidney Failure Help Drive Illnesses From Extreme Heat 2Health News:Scans May Spot People Who'll Benefit From Surgery for OCD 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3
... Executive ... Chairman, SOUTH SAN ... company focused on the discovery,and development of drugs for major medical needs ... will step down today as President and Chief Executive Officer to,pursue another ...
... SAN DIEGO, Oct. 1 Amylin Pharmaceuticals,Inc. ... the U.S. Food and Drug,Administration (FDA) has ... pen-injector devices for administering SYMLIN(R),(pramlintide acetate) injection. ... dosing to improve mealtime glucose control. ...
... Presented at ERS 17th Annual Congress -, ... Inc.,today announced the submission of a pre-market approval ... (FDA) requesting regulatory,approval to market the Emphasys endobronchial ... Zephyr EBV is a minimally invasive and potentially,reversible ...
... have been homeless for any period of time after ... problems accessing health care than those with stable housing ... of Archives of Pediatrics & Adolescent Medicine, one of ... any period of time after leaving the foster care ...
... 1 Highlands Behavioral,Health System, a UHS facility, ... of Excellence for teens in crisis. The new ... Highlands Behavioral,Health ( http://www.highlandsbhs.com ) in Littleton, Colo. ... said the,Adolescent Center of Excellence represents an expansion ...
... was recently announced,as a silver winner in ... by,ComPsych Corporation. Concentra was selected based on ... achieved results. Concentra, a leader in ... commitment to better health and wellness among ...
Cached Medicine News:Health News:Renovis Announces Management Changes 2Health News:Renovis Announces Management Changes 3Health News:Renovis Announces Management Changes 4Health News:Renovis Announces Management Changes 5Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 3Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 4Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 2Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 3Health News:Poor health care access common among youth leaving foster system 2Health News:Poor health care access common among youth leaving foster system 3Health News:New Denver Area Program Developed For Teens in Crisis 2Health News:Concentra Honored With Silver Health at Work(SM) Award by ComPsych(R) Corp. 2
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Sol, 80 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... Pachymeter [i.e., PalmScan P2000] device is ... which incorporates A-mode pulsed-echo ultrasound,technology, and ... measure the corneal thickness (CT) and,epithelium ... P2000 includes two software user,interfaces; a ...
Medicine Products: